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Abstract 
The selective cannabinoid CB1 receptor antagonist SR141716 has been shown to 
precipitate physical signs of withdrawal in A ^tetrahydrocannabinol (THC)-dependent 
rats; however, the affective state associated with this withdrawal state has not yet been 
well characterized. Thus, the aim of present study was to examine the physical and 
affective consequences of SR141716-precipitated THC withdrawal in male Sprague-
Dawley rats. Rats were injected with THC (5 mg/kg, i.p.) or its vehicle twice daily for 13 
consecutive days, and challenged with SRI 41716 (1 mg/kg, i.p.) or its vehicle 1 h later 
on days 3, 5, 7, 9, 11, and 13. Consistent with previous reports, SR141716 induced signs 
of physical withdrawal (e.g., increased scratching) in THC-dependent animals. The 
affective state induced by both SR141716-precipitated THC withdrawal and naloxone-
precipitated morphine withdrawal were then assessed using a tactile cue-conditioning 
paradigm, and withdrawal-induced anxiety was measured using a test battery consisting 
of the emergence test, elevated plus maze (EPM), and social interaction test. Precipitated 
morphine withdrawal induced both significant conditioned cue avoidance and 
anxiogenic-like behaviour; however, precipitated THC withdrawal failed to produce a 
conditioned cue avoidance, and did not induce anxiety in a manner different from that 
produced by administration of THC alone. These findings provide novel evidence that 
unlike opiate withdrawal, cannabinoid withdrawal manifests physical signs of 
withdrawal, but does not induce anxiety or a dysphoric state. Although there may be 
overt physical similarities between opiate and cannabinoid withdrawal, these syndromes 
likely represent distinct emotional and subjective states. 
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Marijuana is indisputably one of the most widely used illicit drugs, with 32.7% of 
the Canadian population having tried it more than once (Health Canada, 2008). Its use is 
especially prevalent among adolescents. A recent Health Canada survey revealed that 
60% of 15-24-year-old individuals reported using marijuana at least once, and nearly 1 in 
10 of those individuals reported using it on a daily basis (Health Canada, 2007). Despite 
the large number of regular users, there is contention whether marijuana produces 
physical dependence in which cessation results in a withdrawal syndrome typified by 
physical and emotional distress—a characteristic of almost all drugs of abuse. Laboratory 
and clinical studies have reliably demonstrated withdrawal syndromes using 
psychostimulants, narcotics, ethanol, and nicotine (Young & Herling, 1986; Yokel, 
1987), but studies using A9-tetrahydrocannabinol (THC)—the main psychoactive 
constituent of marijuana—or other synthetic cannabinoids, have been less convincing. 
Currently, a cannabis withdrawal syndrome is not included in the fourth edition of 
the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV, 2000), which states 
that this syndrome is of limited clinical significance. However, human studies of cannabis 
withdrawal provide conflicting evidence. Inpatient studies, dating back more than 60 
years, showed a variety of signs following abrupt discontinuation of marijuana smoking 
or oral THC, including sleep disturbances, mood changes, decreased appetite, and nausea 
(Haney, Ward, Comer, Foltin, & Fischman, 1999a; Haney, Ward, Comer, Foltin, & 
Fischman, 1999b; Jones & Benowitz, 1976; Jones, Benowitz, & Bachman, 1976; 
Williams, Himmelsbach, Wikler, Ruble, & Lloyd, 1946). Nevertheless, other similar 
inpatient studies did not observe withdrawal effects after abrupt cessation from 
marijuana, oral THC, or hashish (Greenberg, Mendelson, Kuehnle, Mello, & Babor, 
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1976; Stefanis, Liakos, Boulougouris, Dornbush, & Ballas, 1976). Retrospective and 
outpatient studies have yielded more consistent results, reporting many of the same 
withdrawal signs as inpatient studies, in frequent marijuana users when they abstained 
from smoking marijuana (Budney, Novy, & Hughes, 1999; Budney, Hughes, Moore, & 
Novy, 2001; Budney, Moore, Vandrey, & Hughes, 2003; Kouri & Pope, 2000; Wiesbeck, 
Schuckit, Kalmijn, Tipp, Bucholz, & Smith, 1996). Recent reviews of the cannabis 
withdrawal literature have attempted to assimilate the findings to better characterize a 
cannabinoid withdrawal syndrome, but even these articles disagree. Two reviews 
concluded that a withdrawal syndrome in humans is reliable, valid, and clinically 
important (Budney, Hughes, Moore, & Vandrey, 2004; Lichtman & Martin, 2002). 
Moreover, one review likened cannabis withdrawal to tobacco withdrawal and proposed 
diagnostic criteria for the syndrome (Budney et al., 2004). Smith (2002), on the other 
hand, concluded that strong evidence base is lacking for a cannabis withdrawal syndrome 
and that cannabis does not appear to induce a distinct withdrawal pattern in a manner 
similar to other drugs of abuse. Although they are ultimately opposed, the reviews agree 
that several relevant areas of cannabis withdrawal have yet to be explored and that more 
controlled research would be useful. Animal studies offer greater experimental control, 
but because human studies provide few objective measures of cannabis withdrawal and 
rely heavily on subjective accounts, animal studies have had little direction for examining 
somatic withdrawal signs. 
Early animal studies of cannabis withdrawal also yielded mixed results. Studies of 
rhesus monkeys withdrawing from chronic intravenous, intramuscular, or oral THC 
found transient signs, including aggression, anorexia, irritability, hair-pulling, and 
Administration of 3 
scratching (Beardsley, Balster, & Harris, 1986; Fredericks & Benowitz, 1980; 
Kaymakcalan, 1973; Stadnicki, Schaeppi, Rosenkrantz, & Braude, 1974). One study 
using rhesus monkeys, however, failed to observe any withdrawal signs following abrupt 
discontinuation of repeated intravenous THC (Harris, Waters, & McLendon, 1974). 
Studies using rats, dogs, and pigeons also failed to observe THC withdrawal signs (Leite 
& Carlini, 1974; Dewey, Jenkins, O'Rourke, & Harris, 1972; McMillan, Dewey, & 
Harris, 1971; McMillan, Harris, Frakenheim, & Kennedy, 1970). These inconsistent 
findings have been attributed to methodological difficulties associated with using an 
spontaneous withdrawal procedure. THC is highly lipophilic and, accordingly, has a long 
half-life, causing withdrawal symptoms to be delayed and difficult to quantify (Wall, 
Sadler, Brine, Taylor, & Perez-Reyes, 1983). 
Discovery of the endogenous cannabinoid system and identification of 
cannabinoid receptors signified a major advancement in cannabinoid research. The 
involvement of the endogenous cannabinoid system in cognition, appetite, pain 
perception, and motor regulation has served to clarify the actions of cannabinoids. Two 
cannabinoid receptors have been cloned: the CB1 cannabinoid receptor (Matsuda, Lolait, 
Brownstein, Young, & Bonner, 1990), which is abundant in the brain, and the CB2 
cannabinoid receptor (Munro, Thomas, & Abu-Shaar, 1993), which is localized primarily 
outside the central nervous system. Several lines of evidence suggest that the CB1 
cannabinoid receptor is responsible for the central effects of cannabinoids, one source of 
evidence being the development and effectiveness of the selective CB1 receptor 
antagonist SRI41716 (^-(piperidin-1 -yl)-5-(4-chlorophenyl)-1 (2,4-dichlorophenyl)-4-
methyl-1 //-pyrazole carboxamide HC1; Rinaldi-Carmona et al., 1994). SR141716 has 
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been shown to attenuate many of the pharmacological effects of cannabinoids in 
laboratory animals including rodents, dogs, rhesus monkeys, and also in humans 
(Compton, Aceto, Lowe, & Martin, 1996; Lichtman et al., 1998; Vivian et al., 1998; 
Huestis et al., 2001). More importantly, the development of SR141716 provided a 
valuable new model for withdrawal studies. Administering SR141716 to cannabinoid-
dependent animals produces an immediate and quantifiable withdrawal syndrome, thus, 
apparently eradicating the challenges of measuring spontaneous withdrawal. Rats made 
tolerant to THC and challenged with SR141716 have been found to exhibit a dramatic 
withdrawal syndrome characterized by wet-dog shakes, facial rubbing, forepaw 
fluttering, and scratching (Aceto, Scates, Lowe, & Martin, 1995; Tsou, Patrick, & 
Walker, 1995). 
Precipitated withdrawal has proven to be a reliable method for studying opiate 
withdrawal, a better-established syndrome than cannabis withdrawal. The nonselective 
opioid receptor antagonist naloxone, when administered to morphine-dependent rats, 
induces clear behavioural signs of withdrawal including wet-dog shakes, writhing 
behaviour, self-care, and exploration (Wei, Loh, & Way, 1973; Gellert & Holtzman, 
1978; Higgins, Nguyen, Joharchi, & Sellers, 1991; Maldonado, Stinus, Gold, & Koob, 
1992; Espejo, Cador, & Stinus, 1995; Frenois, Cador, Caille, Stinus, & Le Moine, 2002). 
In addition to somatic signs, morphine withdrawal is characterized by a dysphoric state, 
described as anxiety, depression, restlessness, and irritability in humans (American 
Psychiatric Association, 2000; Haertzen & Hooks, 1969). This finding is supported by 
the demonstration of a robust conditioned place avoidance (CPA) to an environment 
paired with naloxone-induced precipitated withdrawal in morphine-dependent rodents, 
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which is indicative of a dysphoric state (Mucha, 1987; Higgins et al., 1991; Higgins & 
Sellers, 1994; Frenois et al., 2002; Rothwell, Thomas, & Gewirtz, 2009). Studies 
specifically of anxiogenic-like behaviour during morphine withdrawal, however, have 
yielded equivocal results in animals. 
The elevated plus maze (EPM) is commonly used to measure anxiety in 
rodents. The administration of naloxone to either morphine-dependent rats, or rats acutely 
exposed to morphine, dose-dependently suppresses time spent exploring the open arms of 
the EPM, thus indicating withdrawal-induced anxiety (Schulteis, Yackey, Risbrough, & 
Koob, 1998; Zhang & Schulteis, 2008). However, recent studies of naloxone-precipitated 
morphine withdrawal have found the opposite effects in mice on the EPM; that is, mice 
undergoing opioid withdrawal spent significantly more time exploring the open arms 
(Hodgson, Hofford, Norris, & Eitan, 2008; Buckman, Hodgson, Hofford, & Eitan, 2009). 
Withdrawal-potentiated acoustic startle (Rothwell et al., 2009) and defensive probe 
burying (Emmett-Oglesby, Harris, Lane, & Lai, 1984; Higgins & Sellers, 1994) have also 
been observed as indicators of anxiety in rats acutely exposed to morphine. Few other 
behavioural measures of anxiety have been used to examine naloxone-precipitated 
morphine withdrawal-induced anxiety, and little research exists for anxiogenic-like 
behaviour during cannabinoid withdrawal. One study using the defensive withdrawal test 
in rats undergoing SR141716-precipitated withdrawal from the potent synthetic 
cannabinoid HU-210 (Rodriguez de Fonseca, Rocio, Carrera, Navarro, Koob, & Weiss, 
1997) and a recent study of mice undergoing antagonist-precipitated THC withdrawal on 
the EPM are the only to report anxiety-like effects of cannabinoid withdrawal (Huang, 
Liu-Chen, & Kirby, 2010). 
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The present study sought to elucidate both the behavioural effects and affective 
state associated with THC withdrawal. Rats chronically exposed to THC were assessed 
for behavioural signs of SR141716-precipitated withdrawal (Experiment 1) and tested in 
a conditioned cue avoidance task for withdrawal-induced dysphoria (Experiment 2). The 
conditioned cue avoidance task is similar to the CPA task but, rather than pairing a 
distinct environment with a drug, the conditioned cue avoidance task used in this study 
employs tactile differentiation between drug- and vehicle-paired floors within a single 
compartment. This procedure requires animals to physically touch the drug-paired cue in 
order to elicit the conditioned motivational response that presumably underlies the 
preference or avoidance for the cue (Vezina & Stewart, 1987a). Thus, the problem of 
detecting cues from a distance, as is possible with visual, auditory, and olfactory cues, is 
eradicated. Tactile cues alone have been repeatedly demonstrated as an effective 
conditioning procedure in both rats (e.g., Vezina & Stewart, 1987a; 1987b; Cunningham 
& Niehus, 1993; Roma & Riley, 2005) and mice (e.g., Cunningham, Ferree, & Howard, 
2003; Cunningham, Henderson, & Bormann, 1998; Cunningham, & Prather, 1992). In 
fact, multimodal stimuli have been found to be redundant in place conditioning and of no 
significant benefit, particularly when a tactile stimulus is included (Cunningham, Patel, & 
Milner, 2006). Tactile conditioned cue avoidance is produced by naloxone-precipitated 
morphine withdrawal following repeated conditioning sessions (Parker & Joshi, 1998; 
Manwell et al., 2009) and following a single conditioning session (Parker, Cyr, Santi, & 
Burton, 2002). This avoidance procedure is novel to cannabinoid withdrawal studies, and 
thus the present study sought to determine whether the same phenomenon occurs with 
SR141716-precipitated THC withdrawal. 
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An additional advantage of the tactile cue avoidance procedure is that it is not 
dependent on the hippocampus, unlike the CPA procedure. CB1 receptors are expressed 
in high abundance within the hippocampus (Glass, Dragunow, & Faull, 1997; Herkenham 
et al., 1990; Tsou, Brown, Sanudo-Pena, Mackie, & Walker, 1998) and administration of 
cannabinoids has been shown to reduce hippocampal theta oscillations, implicated in 
memory encoding (Robbe et al., 2006), thereby impairing hippocampus-dependent 
memory (e.g., Heyser, Hampson, & Deadwyler, 1993; Lichtman, Dimen, & Martin, 
1995; Lichtman & Martin, 1996; Stiglick & Kalant, 1982). Thus, place conditioning 
procedures that depend on spatial location cues are impractical for measuring the 
rewarding or aversive effects of cannabinoids. This may explain the lack of CPA in mice 
undergoing SR141716-precipitated THC withdrawal (Hutcheson et al., 1998). The 
conditioned cue avoidance task was repeated on rats undergoing naloxone-precipitated 
morphine withdrawal in order to confirm the validity of the apparatus and procedure, and 
for comparison with the results of SR141716-precipitated THC withdrawal conditioned 
cue avoidance. 
The subjective effects of precipitated THC-withdrawal were also assessed using 
an anxiety test battery, which included the emergence test, the EPM, and the social 
interaction task (Experiment 3). This test battery was again repeated using naloxone-
precipitated morphine withdrawing rats, first, for comparison with those measures in rats 
experiencing a THC withdrawal syndrome and, second, because the emergence test is a 
novel measure of anxiogenic-like behaviour induced by naloxone-precipitated morphine 
withdrawal. 
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Specific hypotheses and expected results for each experiment are presented 
below. 
Methods and Materials 
Subjects 
Subjects were 156 experimentally naive male Sprague-Dawley rats. Of these, 102 
rats weighed between 201 and 225 g at time of shipment (Charles River Laboratories, St. 
Constant, Quebec, Canada) and 54 rats were bred in house from Sprague-Dawley rats 
originating from Charles River Laboratories. Animals bred in house were weaned on 
postnatal day 23 and pair-housed. They were maintained on a 12-h reverse light-dark 
cycle (7:00 am-7:00 pm) and given ad libitum access to food and water except during 
testing. Experimental testing commenced when rats weighed at least 200 g. Rats received 
from Charles River Laboratories were pair-housed as described for in-house bred rats and 
allowed to acclimate to the housing conditions for a minimum of 5 days. All animals 
were gently handled for a minimum of 4 days prior to any testing. This study was 
reviewed and approved by the Wilfrid Laurier University Animal Care Committee, and 
all experimental procedures were carried out in accordance with the Canadian Council on 
Animal Care Guide to the Care and Use of Laboratory Animals (CCAC, vol. 1, 1993). 
Drugs 
THC (THC Pharm GmbH, Frankfurt, Germany) and SR141716 (Rimonabant; 
Onbio Inc., Richmond Hill, ON, Canada) were first dissolved in ethanol then mixed with 
a few drops of TWEEN-80 (polyoxyethylene sorbitan monooleate; ICN Biomedicals, 
Seven Hills, NSW, Australia). The solution was stirred under a stream of nitrogen gas 
until all ethanol was evaporated. Physiological saline was then added and the suspension 
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was well mixed. The final vehicle suspension contained 0.75% TWEEN-80 and 0.9% 
NaCl. THC and SRI 41716 were administered at a dose of 5 mg/kg and 3 mg/kg, 
respectively. 
Morphine hydrochloride (CDMV, St. Hyacinth, Quebec, Canada) and naloxone 
hydrochloride (Tocris, Ellisville, Missouri, USA) were dissolved in 0.9% saline and 
administered at a dose of 5 mg/kg and 1 mg/kg, respectively. 
All drugs were administered intraperitoneally (i.p.) in a volume of 1 ml/kg body 
weight. Equivalent volumes of either saline or TWEEN-80/saline were used for vehicle 
control treatments. 
Experiment 1: Behavioural Assessment of SR141716-precipitated THC Withdrawal 
Animals were examined for somatic signs of SR141716-precipitated THC 
withdrawal for three reasons: 1) to ensure that the selected doses of THC and SR141716 
produced a quantifiable physical withdrawal syndrome, 2) to exclude the possibility that 
SR141716 alone produces somatic effects to the same degree as THC withdrawal: 
SR141716 itself has been found to induce behaviour similar to cannabinoid withdrawal in 
rodents (Aceto et al., 1995; Compton et al., 1996; Rodriguez de Fonseca et al., 1997; 
Aceto, Scates, Razdan, & Martin, 1998), and 3) to ensure that the timing for measuring 
the affective state of animals experiencing SR141716-precipitated THC withdrawal 
would encompass the physical display of withdrawal signs. 
It was expected that all animals treated with SR141716 would demonstrate a 
modest increase in withdrawal-like behaviours, but that animals repeatedly pre-exposed 
to THC would exhibit pronounced somatic withdrawal signs, characterized by increased 
scratching, wet-dog shakes, and facial rubbing. Furthermore, because precipitated 
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withdrawal indicates physical dependence on a drug (Aceto, Scates, & Martin, 2001), it 
was anticipated that increasing the number of THC exposures would augment the 
SRI 41716-precipitated withdrawal. 
Apparatus 
Behavioural signs of SR-141716-precipitated THC withdrawal were observed in 
an experimental chamber (61 x 26 x 40 cm) consisting of clear acrylic sides and top, and 
a black ABS plastic floor, situated in a dimly lit room (37 Lux at apparatus level). 
Activity was recorded by a video camera positioned 75 cm in front of the apparatus. 
Procedure 
A procedural timeline is presented in Table 1. Animals were injected twice daily 
with either TWEEN-80/saline (n=8) or THC («=8) for 13 consecutive days at 
approximately 9:00 am and 9:00 pm. The first injection occurred at 9:00 pm on day 1 and 
the last injection at 9:00 am on day 13. All rats were injected 1 h following the 9:00 am 
drug injections with TWEEN-80/saline on days 3, 7, and 11 and with SR141716 on days 
5, 9, and 13. Rats were then immediately placed individually in experimental chambers 
for a period of 30 min on both vehicle and SR141716 challenge days. Video recorded 
activity was manually scored by an observer blind to group allocations using ODLog 
software (Macropod Software, 2001; www.macropodsoftware.com). Rats were assessed 
for behavioural signs of withdrawal, including scratching, wet-dog shakes, and facial 
rubs, for 5 min starting at 10 min into the 30 min trial and for the last 5 min of each trial. 
These assessment time points were selected based on previous reports that physical signs 
of SR141716-precipitated THC withdrawal emerge approximately 10 min following 
SR141716 administration and persist throughout a 1 h period (Aceto et al., 1995; Tsou et 
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al., 1995). Scratching was defined as hindlimb scratching and was recorded as time (s) 
spent scratching by animals during each 5 min observation segment. Wet-dog shakes 
were defined as paroxysmic shuddering of the head, neck, and trunk, reminiscent of 
purposeful movement in dogs. Facial rubs were defined as the animal wiping any part of 
its head with both forelimbs. Wet-dog shakes and facial rubs were counted as number of 
events per each 5 min observation segment. 
Statistical Analysis 
As shown in Figure 1, the second observation segment yielded more pronounced 
withdrawal signs relative to the first observation segment. Thus, only the second segment 
was used for the statistical analysis. Somatic withdrawal signs associated with 
SR141716-precipitated THC withdrawal were analyzed using a three-factor [group (T-
VEH vs. THC) x treatment (S-VEH vs. SR141716) x day] mixed design ANOVA with 
repeated measures on the second two factors. Each behavioural measure was analyzed 
individually. 
Where significant main effects were found, pairwise comparisons were conducted 
using Bonferroni-adjusted t-tests. Significant two-way interactions were followed by one-
way tests of the simple main effects. All analyses were carried out using PASW 18.0 for 
Macintosh (SPSS, Chicago, IL, USA) with an alpha level of 0.05. 
Results 
Data for the physical signs of SR141716-precipitated THC withdrawal are 
presented in Figure 1. The three-factor mixed design ANOVAs revealed a significant 
main effect of treatment on all three measures: time spent scratching [F(l,9)=16.343, 
p=.003; Fig. 1A], number of wet dog shakes [F(l,9)=21.522, p=.001; Fig. IB], and 
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number of facial rubs [F(l,9)=6.469, p=.032; Fig. 1C] were increased by SR141716 in all 
animals. For time spent scratching, there was also a main effect of group [F(l,9)=5.836, 
p=.039], such that THC animals spent significantly more time scratching than vehicle 
control animals. Furthermore, time spent scratching yielded a significant group by 
treatment interaction [F(l,9)=5.472, p=.040]. One-way tests of the simple main effects 
revealed that THC animals spent a significantly more time scratching than vehicle control 
animals when treated with SR141716 [F(l,14)=5.811, p=.030; Fig. 2]. No significant 
difference in time spent scratching was observed between groups when treated with the 
vehicle for SRI41716. 
Discussion 
The results of Experiment 1 are in agreement with previous studies (e.g., Aceto et 
al., 1995; Tsou et al., 1995; Compton et al., 1996; Rodriguez de Fonseca et al., 1997; 
Aceto et al., 1998; Aceto et al., 2001) showing that treatment with SR141716 alone 
induces limited withdrawal-like behaviour, and that pre-exposure to THC results in a 
pronounced increase in these physical withdrawal signs. As has been suggested, this 
effect may be a result of antagonistic effects of SRI41716 on the endogenous 
cannabinoid system, ultimately disrupting its tonic inhibitory action in the presence of 
THC (Aceto et al., 2001; Sanudo-Pena, Tsou, Delay, Hohman, Force, & Walker, 1997). 
Alternatively, it has been proposed that SR141716 may act as an inverse agonist on the 
CB1 receptor (Compton et al., 1996; Richardson, Aanoson, & Hargreaves, 1997). It is 
important to note also, that rats undergoing spontaneous withdrawal from THC show 
modest or no physical symptoms of withdrawal (Aceto, Scates, Lowe, & Martin, 1996; 
Diana, Melis, Muntoni, & Gessa, 1998). Of course, this could be due to the long half-life 
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of THC as previously mentioned, but a synergistic effect of THC and SRI41716 may be 
a reasonable explanation for the apparent withdrawal symptoms. 
Scratching was found to be the most reliable physical sign of SR141716-
precipitated THC withdrawal. Although SR141716 alone increased scratching behaviour, 
time spent scratching also specifically reflected withdrawal from THC, whereas wet-dog 
shakes and facial rubbing could not be differentiated from an effect of merely SR141716. 
During SR141716-vehicle challenges, however, facial rubbing was representative of the 
well-documented locomotor-reducing effects of cannabinoids (Schramm-Sapyta, Young, 
Chaudhry, Wilson, Swartzwelder, et al., 2007; Oviedo, Glowa, & Herkenham, 1993; Hill, 
Gorzalka, & Choi, 2004). Slight tolerance to THC-induced locomotor suppression was 
evident on the second and third vehicle days, which is typical during chronic cannabinoid 
exposure (Oviedo et al., 1993; Hill et al., 2004). It should be noted that, in addition to the 
quantified behavioural signs of SR141716-precipitated THC withdrawal, other overt 
somatic symptoms were observed but were not systematically measured. Stretching, 
arched back, and diarrhea occurred in THC-treated rats when challenged with SR141716, 
which have been reported in previous cannabinoid withdrawal studies and were 
associated with precipitated withdrawal (Aceto et al , 1995, Aceto et al., 2001, Lichtman 
et al., 1998). These observations suggest that SR141716 produces a fundamentally 
different effect in THC-dependent rats than in nondependent rats. 
As mentioned previously, there was a generally smaller effect of SRI 41716 on 
THC-treated rats at the 10-15 min observation segment, the presumed onset of 
withdrawal, and a more pronounced effect during the 25-30 min segment. There was no 
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significant effect of day, which suggests that animals were physically dependent on THC 
by the first day of SR141716 treatment. 
Experiment 2: SR141716-precipitated THC Withdrawal-induced Cue-conditioning 
Avoidance conditioning is a sensitive measure of the aversive properties of drug 
withdrawal (Koob, Stinus, Le Moal, & Bloom, 1989; Mucha, 1987; Mucha, 1991; Mucha 
& Iversen, 1984). Two unbiased cue-conditioning experiments were conducted to 
investigate whether the physical signs of SR141716-precipitated THC withdrawal were 
coupled with dysphoria: Experiment 2A examined conditioned cue avoidance following a 
single vehicle- and drug-cue pairing, and Experiment 2B examined conditioned cue 
avoidance following three separate vehicle- and drug-cue pairings. The drug-cue pairings 
conditioned THC-treated animals to the SR141716-precipitated withdrawal state, and 
THC-vehicle-treated animals to the effects of SR141716 alone. Similarly, in morphine 
control groups, morphine-treated animals were conditioned to the naloxone-precipitated 
withdrawal state during drug-cue pairings, and morphine vehicle-treated animals to the 
effects of naloxone alone. Although naloxone-precipitated morphine withdrawal-induced 
cue avoidance has been observed following only one vehicle- and one drug-pairing 
(Parker et al., 2002), both one cycle and three cycle cue-conditioning schedules were 
used to allow for repeated drug treatment in an attempt to increase the severity of 
withdrawal and related dysphoria. 
It was predicted that an avoidance to the THC withdrawal-paired cue would be 
observed, indicating that a dysphoric state is associated with cannabinoid withdrawal, and 
the magnitude of this withdrawal would be greater following three cycles of conditioning 
relative to a single cycle. In agreement with previous place- and cue-conditioning studies, 
Administration of 15 
it was also anticipated that naloxone-precipitated morphine withdrawal would produce a 
conditioned avoidance to the withdrawal-paired cue that varied in severity according to 
the number of conditioning cycles. 
Apparatus 
The cue-conditioning task was performed in eight identical unbiased chambers 
(61 x 29 x 30 cm high) in a room dimly illuminated by four 13 W compact fluorescent 
red lamps (10 Lux measured at the apparatus floor). The chambers were constructed of 
black UHMW polyethylene walls, black wire mesh tops, and two texturally different 
interchangeable floor types. One floor was made of ABS plastic with holes arranged in a 
grid pattern (holes were 1 cm in diameter, spread 1 cm apart with a depth of 2 mm; 
termed "hole" floor). The other floor was made of textured plastic sheeting typically used 
for fluorescent ceiling light covers. These provided a rough "bumpy" surface (bumps 
were 1 mm high, each 2.5 x 2.5 cm square contained 100 bumps; termed "bump" floor). 
Activity was recorded by four video cameras mounted 120 cm above the chamber floors 
and images were transmitted via IEEE 1394 interface to a computer in the adjacent room, 
running the ANY-maze Video Tracking System version 4.50 (Stoetling Co., Wood Dale, 
IL, USA). 
Experiment 2A 
Procedure. 
Animals were divided into four groups: THC vehicle+SR141716 (T-VEH+SR, 
n=\2), THC+SR141716-precipitated withdrawal (THC+SR-WD, «=12), morphine 
vehicle+naloxone (M-VEH+NAL, n=S), and morphine+naloxone-precipitated 
withdrawal (MOR+NAL-WD, n=\2). A procedural timeline is shown in Table 2. 
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Animals were injected twice daily with saline, TWEEN-80/saline, THC, or morphine for 
5 consecutive days, at approximately 9:00 am and 9:00 pm. The first injection occurred at 
9:00 pm on day 1 and the last injection at 9:00 pm on day 5. Each animal was tested 
every second day, beginning on day 1 and ending on day 5 with a final test on day 6, at 
approximately the same time of day, during the dark phase of the light/dark cycle. The 
cue-conditioning task was conducted in three phases: preconditioning (day 1, prior to first 
drug injection), conditioning (following the morning injection on days 3 and 5), and test 
(day 6). 
The preconditioning phase consisted of one 15-min undrugged session. During 
this phase, rats were placed in the chambers equipped with one floor type on either side 
(27 x 25 cm) separated by a neutral centre floor made of smooth black ABS plastic (25 x 
9 cm). A baseline measure of time spent on each floor type was recorded, which did not 
show a significant difference between seconds spent on the "hole" or "bump" floors 
indicating that the apparatus provides an unbiased test of conditioned cue preference and 
avoidance. The conditioning phase consisted of two 30-min sessions in which the 
chambers were equipped with alternate floor types. During the first conditioning session, 
a vehicle conditioning session conducted on day 3, THC- and THC-vehicle-treated rats 
were injected with TWEEN-80/saline and morphine- and morphine-vehicle-treated rats 
were injected with saline 1 h following the 9:00 am drug injections and placed in the test 
apparatus immediately afterwards. Two days following the vehicle conditioning session, 
on day 5, the drug-conditioning session, THC- and THC-vehicle-treated rats were 
injected with SR141716 and morphine- and morphine-vehicle-treated rats were injected 
with naloxone 1 h following the 9:00 am drug injections and placed in the test apparatus 
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immediately afterwards. At the conclusion of this phase, SR141716 and naloxone had 
each been paired once with one floor texture and their respective vehicles had each been 
paired once with the other floor texture in a counterbalanced manner, yielding one cycle 
of cue-conditioning. The drug-associated context ("hole" or "bump" floor) was 
counterbalanced across groups. Locomotor activity was also assessed during the 
conditioning phase and was defined by total distance traveled (m), time in motion (s), and 
absolute turn angle (°) as quantified by ANY-maze. One day after the conditioning phase, 
each animal received a 15-min test session, identical to the preconditioning phase. Time 
spent on each floor type was again scored to test the persistence of any cue-conditioned 
preference or avoidance. 
Statistical Analysis. 
Cue-conditioning preference scores were computed by subtracting time spent on 
the SR141716- or naloxone-paired floor during the test day from time spent on the 
SRI41716- or naloxone-paired floor during the preconditioning day. Independent 
samples t-tests were then used to compare T-VEH+SR and THC+SR-WD groups, and to 
compare M-VEH+NAL and MOR+NAL-WD groups. Locomotor activity occurring 
during the conditioning phase was analyzed separately for the aforementioned THC and 
morphine groups using a two-factor [group (T-VEH vs. THC and M-VEH vs. MOR) x 
treatment (S-VEH vs. SR and N-VEH vs. NAL)] mixed design ANOVA with repeated 
measures on the second factor. Each activity measure, including distance traveled, time in 
motion, and absolute turn angle, was analyzed individually. 
Where significant main effects were found, pairwise comparisons were conducted 
using Bonferroni-adjusted t-tests. Significant two-way interactions were followed by one-
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way tests of the simple main effects. All analyses were carried out using PASW 18.0 for 
Macintosh (SPSS, Chicago, IL, USA) with an alpha level of 0.05. 
Results. 
The t-test comparing the change in time spent on the drug-paired floor for T-
VEH+SR and THC+SR-WD groups yielded no significant differences on cue preference 
for one cycle of tactile cue-conditioning (Fig. 3). 
Data from five animals on the SR141716 conditioning session were lost due to 
equipment malfunction. Locomotor activity during the conditioning phase for one cycle 
of cue-conditioning was analyzed accordingly for T-VEH+SR (w=9) and THC+SR-WD 
(n=\0) groups. Data are presented in Figure 4. The two-factor mixed design ANOVAs 
comparing locomotor activity for THC- and THC-vehicle-treated rats revealed no 
significant differences for distance traveled or absolute turn angle measures (Fig. 4, A 
and Fig. 4, C, respectively). The two-factor mixed design ANOVA for time spent in 
motion yielded a significant main effect of group, such that THC-treated animals spent 
significantly less time in motion than THC-vehicle-treated animals [F(l,17)=4.830, 
p=.042; Fig. 4, B]. The group by treatment interaction was also significant for time spent 
in motion [F(l,17)=5.407, p=.033]. One-way tests of the simple main effects for the 
group by treatment interaction revealed that THC-treated animals spent significantly less 
time in motion during the SR141716-vehicle conditioning session [F(l,22)=5.412,/»=.03; 
Fig. 4, B]. There was no significant difference between the two groups for time spent in 
motion during the SR141716 conditioning session. 
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The t-test comparing the change in time spent on the drug-paired floor for M-
VEH+NAL and MOR+NAL-WD groups yielded no significant differences on cue 
preference for one cycle of tactile cue-conditioning (Fig. 5). 
Locomotor activity data for morphine groups during the conditioning phase of 
one cycle of cue-conditioning are presented in Figure 6. The two-factor mixed design 
ANOVAs comparing morphine- and morphine-vehicle-treated rats revealed significant 
main effects of treatment on all three measures of locomotor activity: distance traveled, 
time in motion, and absolute turn angle [F(l,18)=15.602, p=.001; F(l,18)=27.796, 
p<.001; and F( 1,18)= 14.900, p=.001, respectively] were reduced by naloxone in all 
animals. Absolute turn angle also yielded a significant main effect of group 
[F(l,18)=5.889, p=.026], such that morphine-treated animals had a significantly lower 
absolute turn angle than morphine-vehicle-treated animals. 
Experiment 2B 
Procedure. 
An additional group of experimentally-naive animals was used to examine the 
effects of three conditioning cycles. Animals were divided into four groups identical to 
those in Experiment 2A: T-VEH+SR («=8), THC+SR-WD 0=8), M-VEH+NAL («=8), 
and MOR+NAL-WD (n=S). A procedural timeline is shown in Table 3. This procedure 
was identical to that used in Experiment 2A, except that the conditioning phase consisted 
of six sessions (following the morning injection on days 3, 5, 7, 9, 11, and 13) such that 
SR141716 or naloxone had each been paired with one floor texture and their respective 
vehicles each with the other floor texture three times, yielding three cycles of cue-
conditioning. Accordingly, two daily injections of saline, TWEEN-80/saline, THC, or 
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morphine began after preconditioning at 9:00 pm on day 1 and ended at 9:00 am on day 
13. The test followed on day 14. 
Statistical Analysis. 
Cue-conditioning preference scores were calculated and analyzed identical to that 
of Experiment 2 A. Locomotor activity occurring during the conditioning phase was 
analyzed separately for T-VEH+SR and THC+SR-WD groups, and for M-VEH+NAL 
and MOR+NAL-WD using a three-factor [group (T-VEH vs. THC and M-VEH vs. 
MOR) x treatment (S-VEH vs. SR and N-VEH vs. NAL) x day] mixed design ANOVA 
with repeated measures on the second two factors. Activity measures were analyzed 
individually as per Experiment 2A and significant main effects and two-way interactions 
were followed up identical to that of Experiment 2 A. All analyses were carried out using 
PASW Statistics 18.0 for Macintosh (SPSS, Chicago, IL, USA) with an alpha level of 
0.05. 
Results. 
The t-test comparing the change in time spent on the SR141716-paired floor for 
T-VEH+SR and THC+SR-WD groups yielded no significant difference on cue 
preference following three cycles of tactile cue-conditioning (Fig. 7). 
The data for locomotor activity occurring during the conditioning phase of three 
cycles of SR141716-precipitated THC withdrawal-induced cue-conditioning are 
presented in Figure 8. The three-factor mixed design ANOVAs comparing locomotor 
activity for THC-vehicle- and THC-treated animals revealed significant differences on all 
activity measures. Distance traveled (Fig. 8, A) yielded a significant main effect of group 
[F(l,14)=15.296, p=.002], such that THC-treated animals traveled significantly less, 
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treatment [F(l,14)=19.369, p=.001], whereby SR141716 significantly reduced distance 
traveled, and day [F(2,28)=8.949, p=.001]. Bonferroni-adjusted pairwise comparisons of 
the day factor revealed that animals traveled a significantly greater distance on the first 
vehicle- and SR141716-conditioning days than on the second and third conditioning days 
(p=.027 and p=.007, respectively). Time in motion (Fig. 8, B) yielded a significant main 
effect of group [F(l,14)=10.187, p=.007], revealing that THC-treated animals spent 
significantly less time in motion, and day [F(2,28)=3.870, p=.033]. Bonferroni-adjusted 
pairwise comparisons of the day factor revealed that animals spent significantly more 
time in motion on the first vehicle- and SR141716-conditioning day as compared with the 
third conditioning day (p=.03). Absolute turn angle (Fig. 8, C) yielded a significant main 
effect of group [F(l,14)=25.979, p<.001], revealing that THC-treated animals had a 
significantly lower absolute turn angle, treatment [F(l,14)=7.452, p=.016] such that 
SR141716 significantly reduced absolute turn angle, and day [F(2,28)=6.458, p=.005]. 
Bonferroni-adjusted pairwise comparisons of the day factor revealed that absolute turn 
angle was significantly greater on the first vehicle- and SR141716-conditioning days as 
compared with conditioning days two and three (p=.049 and p=.041, respectively). 
The t-test comparing the change in time spent on the naloxone-paired floor for M-
VEH+NAL and MOR+NAL-WD groups revealed a significant difference on cue 
preference for three cycles of tactile-conditioning [t(14)=3.165, p=.003; Fig. 9]. Animals 
treated with morphine spent significantly less time on the naloxone-paired floor during 
the test day than on the preconditioning day as compared with vehicle control animals. 
The data for locomotor activity occurring during the conditioning phase of three 
cycles of naloxone-precipitated morphine withdrawal-induced cue-conditioning are 
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presented in Figure 10. The three-factor mixed design ANOVAs comparing locomotor 
activity for morphine-vehicle- and morphine-treated animals revealed significant 
differences on all activity measures. Distance traveled (Fig. 10, A) yielded a significant 
main effect of group [F(l,14)=7.413, p=.017], such that morphine-treated animals 
traveled significantly greater distance, treatment [F(l,14)=76.222, p<.001], whereby 
naloxone significantly reduced distance traveled, and day [F(2,28)=5.088, p=.013]. 
Bonferroni-adjusted pairwise comparisons of the day factor revealed that distance 
traveled was significantly greater on the first vehicle- and naloxone-conditioning days as 
compared with the second conditioning days (p=.024). Distance traveled also yielded a 
significant group by treatment interaction [F(l,14)=39.823, p<.001] and group by day 
interaction [F(2,28)=6.162, p=.006]. One-way tests of the simple main effects for the 
group by treatment interaction revealed that morphine-treated animals traveled a 
significantly greater distance than vehicle control animals during vehicle-conditioning 
sessions [F(l,14)=18.005, p=.001]. There was no difference between groups on distance 
traveled during naloxone-conditioning sessions. For the group by day interaction, tests of 
the simple main effects revealed that morphine-treated animals traveled a significantly 
greater distance on the third vehicle- and naloxone-conditioning days as compared with 
vehicle control animals [F(l,14)=16.964, p=.001]. No significant differences on distance 
traveled existed between groups on the first or second conditioning days. Time in motion 
(Fig. 10B) yielded a significant main effect of group and treatment [F(l,14)=4.840, 
p=.045 and F(l,14)=68.328, p<.001, respectively], consistent with the morphine-induced 
hyperactivity and naloxone-induced hypoactivity findings of distance traveled. The group 
by treatment interaction [F(l,14)=25.318, p<.001] and group by day interaction 
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[F(2,28)=9.740, p=.001] were also significant for time in motion. One-way tests of the 
simple main effects for the group by treatment interaction revealed that morphine-treated 
animals spent significantly more time in motion during vehicle-conditioning sessions 
than vehicle control animals [F( 1,14)=21.331, p<.001]. No difference was observed 
between groups during naloxone-conditioning sessions. Tests of the simple main effects 
for time in motion revealed a significant difference between groups on the third vehicle-
and naloxone-conditioning days such that morphine-treated rats spent significantly more 
time in motion than vehicle control rats [F(l,14)=16.797, p=.001]. Absolute turn (Fig. 10, 
C) angle yielded a significant main effect of group [F(l,14)=5.270, p=.038], revealing 
that morphine-treated animals had a significantly greater absolute turn angle, treatment 
[F(l,14)=60.810, p<.001], whereby naloxone significantly reduced absolute turn angle, 
and day [F(2,28)=4.261, p=.024]. Bonferroni-adjusted pairwise comparisons of the day 
factor revealed that absolute turn angle was significantly greater on the first vehicle- and 
naloxone-conditioning days as compared with the second conditioning days (p=.042). 
Absolute turn angle also yielded a significant group by treatment interaction 
[F(l,14)=39.823, p<.001] and group by day interaction [F(2,28)=5.745, p=008]. One-
way tests of the simple main effects revealed that morphine-treated animals demonstrated 
a significantly larger absolute turn angle than vehicle control animals during vehicle-
conditioning sessions [F(l,14)=13.689, p=.002], but not during naloxone-conditioning 
sessions. For the group by day interaction, tests of the simple main effects revealed that 
morphine-treated animals had a significantly greater absolute angle than vehicle-treated 
animals on the third vehicle- and naloxone-conditioning days [F(l,14)=17.681, p=.001], 
but not the first or second conditioning days. 
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Discussion 
SR141716-precipitated THC withdrawal failed to produce a conditioned cue 
avoidance following both one and three conditioning cycles, suggesting the absence of a 
dysphoric state. This finding agrees with the previous study of place preference in mice 
withdrawing from THC (Hutcheson et al., 1998), implying that the hippocampal aspect of 
place conditioning is not responsible for the absence of a preference or avoidance. 
SR141716 elicited neither a cue avoidance nor preference in THC naive rats, which is 
consistent with past studies using the place conditioning procedure (Singh, Verty, 
McGregor, & Mallet, 2004; Chaperon, Soubrie, Puech, & Thiebot, 1998; Hutcheson et 
al., 1998); however, other studies have reported a place preference for SR141716 (Cheer, 
Kendall, & Marsden, 2000; Sanudo-Pena et al., 1997). Since SR141716 had no 
motivational effects in the paradigm used in this study, it is unlikely that the antagonist 
blocked any aversive consequences of THC withdrawal. Thus, an opposing rewarding 
action of SR141716 could not account for the absence of a withdrawal associated cue 
avoidance. Consistent with past research (Parker et al., 2002; Parker & Joshi, 1998; 
Man well et al., 2009), naloxone-precipitated morphine withdrawal produced a distinct 
conditioned cue avoidance, but only following three cycles of conditioning. Naloxone 
produced a slight avoidance in morphine naive rats, though this is a common effect of 
naloxone and it is reliably enhanced by pre-treatment with morphine (Mucha & Herz, 
1985; Mucha & Iversen, 1984; Parker & Rennie, 1992; Parker & Joshi, 1998). 
It was evident after both one and three cycles of cue-conditioning that THC 
suppressed locomotor activity, which is consistent with previous findings (Singh, 
McGregor, & Mallet, 2005; Norwood, Cornish, Mallet & McGregor, 2003; Arevalo, de 
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Miguel, & Hernandez-Tristan, 2001). SR141716 also slightly reduced locomotor activity 
irrespective of drug history. This became apparent only during three cycles of cue-
conditioning as locomotor activity was elevated on the first conditioning day, likely a 
result of novelty-seeking behaviour. Previous studies, however, have demonstrated that 
SR141716 typically does not influence locomotor activity (Arevalo et al., 2001; Gardner 
& Mallet, 2006; Verty, McFarlane, McGregor, & Mallet, 2004a; Verty, McFarlane, 
McGregor, & Mallet, 2004b; Verty, McGregor, & Mallet, 2004; Singh et al., 2004). This 
unusual effect of SRI41716 may be explained by the order in which animals were 
conditioned to vehicle and SR141716: SR141716 conditioning trials followed vehicle 
conditioning trials by one session and thus, novel exploratory behaviour would be 
generally lower on those days than on vehicle conditioning days. Morphine generally 
stimulated locomotor activity, which escalated with repeated exposure and completely 
abolished the novelty-seeking effect observed in morphine-naive rats. Naloxone 
attenuated morphine-induced hyperactivity and reduced locomotor activity in drug naive 
animals. These findings are in agreement with previous studies of opiate-induced activity 
(Kuribara, 1995; Singh et al., 2004). 
Experiment 3: SR141716-precipitated THC Withdrawal-induced Anxiety 
The dysphoric state typically associated with drug withdrawal often incorporates a 
feeling of anxiety. Although a dysphoric state was not observed in THC-withdrawing rats 
on the conditioned cue avoidance task, evidence exists for the involvement of 
corticotropin-releasing factor (CRF) systems and other stress-related hormones during 
cannabinoid withdrawal (Rodriguez de Fonseca et al., 1997). Furthermore, results from a 
recent study of opiate withdrawal suggest that dysphoric and anxiogenic manifestations 
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may be mediated by distinct neural systems (Rothwell et al., 2009). Thus, it remains 
possible that cannabinoid withdrawal may produce anxiety-like behaviour without 
producing dysphoria and, as such, anxiety associated with precipitated THC withdrawal 
was examined using a test battery comprising the emergence test, EPM, and social 
interaction test (Morley, Gallate, Hunt, Mallet, & McGregor, 2001). 
The emergence test involves conflict between the desire to explore and the desire 
to avoid the anxiogenic stimuli of open space (Crawley & Goodwin, 1980). Similarly, the 
EPM involves conflict between the desire for exploration and for avoidance of open and 
high spaces (Lister, 1990). Both of these tasks are considered to be measures of 
generalized anxiety since agents used to alleviate generalized anxiety disorder symptoms 
modify defensive behaviours evoked by the models (Pellow, Chopin, File, & Briley, 
1985). The social interaction test involves the anxiety rats display towards an unfamiliar 
conspecific, wherein anxiety is indicated by reduced contact or defensive behaviour. The 
test has been extensively validated with different classes of drugs for both anxiogenic and 
anxiolytic effects (File, 1980; File, 1985). These three anxiety measures were selected 
and used in conjunction to obtain reliable observations and to control for possible drug 
effect interference. For example, both the emergence test and EPM rely on locomotor 
activity and since THC suppresses locomotor activity these measures may not be suitable 
for examining the associated anxiety. Thus, the social interaction test may provide a more 
reliable measure of anxiety in THC groups. Furthermore, it is possible that the emergence 
test and EPM are hippocampal-dependent, which would be disturbed by THC, and 
therefore the hippocampal-independent social interaction test may again be a better 
measure. 
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Few studies have examined cannabinoid withdrawal-induced anxiety. As 
mentioned, a very recent study demonstrated anxiety-like effects of SR141716-
precipitated THC withdrawal in mice on the EPM (Huang et al., 2010), but this has not 
been shown with rats nor corroborated with other behavioural measures of anxiety. 
Anxiety associated with opioid withdrawal has been studied more closely, and yielded 
fairly consistent results. Increased anxiogenic-like behaviour has been observed on the 
EPM in rats experiencing spontaneous and naloxone-precipitated morphine withdrawal 
following both acute or repeated morphine exposure (Schulteis et al , 1998; Zhang & 
Schulteis, 2008). Limited research exists on the emergence test and social interaction test 
for morphine withdrawing animals. One study found increased social interaction between 
morphine withdrawing rats paired with control rats; however, this observation was 
deduced to be a result of behaviour associated with morphine withdrawal rather than 
anxiety (Grasing, Wang, & Schlussman, 1996). 
Despite the absence of a dysphoric state in Experiment 2, it was predicted that the 
physical symptoms exhibited by rats withdrawing from THC may instigate a feeling of 
anxiety and thus, anxiogenic-like behaviour would be observed on the emergence test, 
EPM, and social interaction test. Precipitated morphine withdrawal was expected to 
induce generalized anxiety on all three measures in accordance with previous research 
and with the dysphoric state demonstrated in Experiment 2. 
Emergence Test 
The emergence test was conducted in a dimly lighted room illuminated by one 13 
W compact fluorescent red lamp (4 Lux at apparatus floor level) within an apparatus 
consisting of a 120 x 120 x 45 cm white melamine arena with a black ABS plastic floor 
Administration of 28 
and a 40 x 24 x 17 cm black melamine hide box. The rat was placed in the hide box at the 
beginning of the test period. Activity was recorded by a video camera mounted 225 cm 
above the apparatus, using the ANY-maze Video Tracking System, as previously 
described. Scored behaviours included latency to emerge from the hide box, number of 
open-field entries, and time spent in the open field. 
Elevated Plus Maze 
The EPM consisted of two open (52 x 12 cm) and two closed (52 x 12 x 40 cm) 
black melamine arms arranged in a cross-elevated position, 53 cm above the floor. The 
EPM was conducted in a dark room illuminated by one 13 W compact fluorescent red 
lamp (2 Lux at maze floor level) and activity was recorded by one camera mounted 140 
cm above the apparatus, using ANY-maze. Scored behaviours included percent number 
of entries to open arms, percent time spent in open arms, and number of entries to closed 
arms. 
Social Interaction 
The social interaction test was conducted in a room dimly illuminated by white 
lights (37 Lux at apparatus level). This test was performed in an experimental chamber 
(61 x 26 x 40 cm) consisting of Plexiglas sides and top, and a black ABS plastic floor. 
Rats were placed in the apparatus for 10 min with a treatment-matched unfamiliar 
conspecific of approximately the same body weight. Activity was recorded by a video 
camera positioned 75 cm in front of the apparatus. An observer blind to group allocations 
manually scored trials using ODLog software. Scored behaviours included sniffing the 
other rat, following the other rat, grooming the other rat, and rearing. 
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Procedure 
Animals were divided into eight groups: THC vehicle+SR141716 vehicle (T-
VEH+S-VEH, «=8), THC vehicle+SR141716 (T-VEH+SR, «=8), THC+SR141716 
vehicle (THC+S-VEH, «=8), THC+SR141716 (THC+SR-WD, w=8), morphine 
vehicle+naloxone vehicle (M-VEH+N-VEH, n=8), morphine vehicle+naloxone (M-
VEH+NAL, rc=8), morphine+naloxone vehicle (MOR+N-VEH, n=S) and 
morphine+naloxone (MOR+NAL-WD, n=8). A procedural timeline is shown in Table 4. 
Rats were injected twice daily with vehicle, THC, or morphine for 5 consecutive days, at 
approximately 9:00 am and 9:00 pm. The first injection occurred at 9:00 pm on day 1 and 
the last injection at 9:00 am on day 5. Rats were injected with vehicle, SR141716, or 
naloxone 1 h following the 9:00 am injection on day 5. Each rat was placed in either the 
emergence test or EPM 15 min later. This delay was selected such that the brief duration 
of these anxiety measures captured animals in a state of withdrawal, as per the onset of 
somatic symptoms. The order in which the emergence test and EPM were conducted was 
counterbalanced across groups. Following both tests, rats were placed in the social 
interaction test. 
Statistical Analysis 
Data for all behavioural measures of emergence test activity (number of open 
field entries, percent of time spent in open field, and latency to exit hide box), EPM 
activity (percent number of open arm entries, percent time spent in open arms, and 
number of entries to closed arms), and social interaction (sniffing, following, grooming, 
and rearing) were analyzed separately for THC and morphine groups by one-way 
ANOVAs, followed by post hoc Tukey tests when significant. All analyses were carried 
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out using PASW 18.0 for Macintosh (SPSS, Chicago, IL, USA) with an alpha level of 
0.05. 
Results 
Emergence Test. 
The one-way ANOVA comparing THC groups revealed a significant difference 
on number of open field entries [F(3,28)=7.579, p=.001]. As shown in Figure 11 (B), post 
hoc analyses revealed that animals receiving THC alone and animals receiving both 
SR141716 and THC made significantly fewer entries to the open field as compared with 
vehicle control animals (p=.002 for both). No significant differences on percent time 
spent in open field (Fig. 11, A) or latency to exit hide box (Fig. 11, C) were observed 
between any THC groups. 
The one-way ANOVA comparing morphine groups revealed significant 
differences on time spent in open field and number of open field entries [F(3,28)=5.479, 
p=.004 and F(3,28)=3.714, p=.023, respectively]. As shown in Figure 12 (A), post hoc 
analyses revealed that animals receiving both morphine and naloxone spent significantly 
less time in the open field as compared with vehicle control animals, animals receiving 
naloxone alone, and animals receiving morphine alone (p=.009; p=.014; p=.019, 
respectively). There were no significant differences between any of the other groups for 
time spent in open field. As shown in Figure 12 (B), post hoc analyses for number of 
open field entries revealed that animals receiving both morphine and naloxone made 
significantly fewer entries to the open field than animals receiving naloxone alone 
(p=.033). No other significant differences were observed between groups on number of 
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open field entries. No significant differences on latency to exit the hide box (Fig. 12, C) 
were observed between any morphine groups. 
Elevated Plus Maze. 
The one-way ANOVA comparing THC groups revealed no significant differences 
on all three EPM measures: percent time spent in open arms (Fig. 13, A), percent number 
of open arm entries (Fig. 13, B), and number of closed arm entries (Fig. 13, C). 
The one-way ANOVA comparing morphine groups revealed significant 
differences on percent number of open arm entries [F(3,28)=5.613, p=.004]. As shown in 
Figure 14 (B), animals receiving both morphine and naloxone made significantly fewer 
entries to the open arms (as a function of total entries to open and closed arms) than 
vehicle control animals and animals receiving naloxone alone (p=.002 and p=.043, 
respectively). No significant differences were observed between any morphine groups on 
percent time spent in open arms (Fig. 14, A) or number of entries to closed arms (Fig. 14, 
C). 
Social Interaction. 
The one-way ANOVA comparing THC groups revealed significant differences on 
time spent sniffing the other rat [F(3,28)=9.992, p<.001; Fig. 15, A], time spent following 
the other rat [F(3,28)=4.869, p=.008; Fig. 15, B], and number of rears [F(3,28)=6.788, 
p=.001; Fig. 15, D]. No significant differences were observed between any THC groups 
on time spent grooming the other rat (Fig. 15, C). Post hoc analyses revealed that animals 
receiving THC alone and animals receiving both THC and SRI 41716 spent significantly 
less time sniffing the other rat as compared with vehicle control animals (p=.002 and 
p<.001, respectively) and compared with animals receiving SR141716 alone (p=.034 and 
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p=.010, respectively). Time spent following the other rat was significantly lower in 
animals treated with both THC and SR141716 compared with vehicle control animals 
and animals receiving SR141716 alone (p=.011 and p=.045, respectively). Number of 
rears significantly differed between animals receiving SR141716 alone and animals 
receiving THC alone, such that THC-treated animals performed significantly fewer rears 
(P=-001). 
The one-way ANOVA comparing morphine groups revealed significant 
differences on time spent sniffing the other rat [F(3,28)=4.753, p=.008; Fig. 16, A], 
following the other rat [F(3,28)=3.074, p=.044; Fig. 16, B], and grooming the other rat 
[F(3,28)=6.441, p=.002; Fig. 16, C]. No significant differences were found on number of 
rears (Fig. 16, D). Post hoc analyses revealed that animals receiving both morphine and 
naloxone spent significantly less time sniffing the other rat compared with vehicle control 
animals and animals receiving naloxone alone (p=.007 and p=.042, respectively). Time 
spent following the other rat significantly differed between vehicle control animals and 
animals treated with both morphine and naloxone, such that morphine-naloxone-treated 
animals showed reduced following time (p=.035). Post hoc analyses for time spent 
grooming revealed that animals treated with naloxone alone, morphine alone, and with 
both morphine and naloxone spent significantly less time grooming the other rat 
compared with vehicle control animals (p=.002, p=.031, and p=.007, respectively). 
Discussion 
SR141716-precipitated THC withdrawal produced some level of anxiety-related 
behaviour, but was not exclusively associated with these behaviours. Rather, THC per se 
appeared to be anxiogenic, which is in agreement with previous reports of cannabinoid-
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associated anxiety (Schramm-Sapyta et al., 2007; Arevalo et al., 2001; Onaivi, Green, & 
Martin, 1990), and this effect was neither reversed nor augmented by subsequent 
SR141716 exposure. Past research has demonstrated that pre-treatment with SR141716 
fails to inhibit the anxiogenic effects of cannabinoids (Arevalo et al , 2001); however, 
SR141716 on its own has also been shown to produce anxiety (Navarro et al., 1997; 
Arevalo et al., 2001), which was not observed in the current study. These findings are in 
accordance with Experiment 2 that SRI 41716 has no motivational effects per se nor 
blocked the consequences of THC. Furthermore, comparable levels of anxiety induced by 
THC and withdrawal from THC may explain the lack of a withdrawal associated 
dysphoric state in the cue-conditioning procedure. 
In contrast to the locomotor assessment in Experiment 2, THC did not reliably 
suppress activity on the anxiety test battery. Although incidence of rearing was reduced 
in THC-treated animals on the social interaction test, the number of entries to the closed 
arms was not altered on the EPM. Interestingly, SR141716 was found to attenuate the 
reduction in rearing induced by THC. This observation is in accordance with previous 
studies that show reversal of CP 55,940- and WIN 55,212-2-induced locomotor effects by 
SR141716 (Arevalo et al., 2001; Rinaldi-Carmona et al., 1994), but contradicts the 
locomotor results of Experiment 2 in the current study. 
Naloxone-precipitated morphine withdrawal clearly induced anxiety-related 
behaviour on all three measures. Neither morphine nor naloxone on its own elicited 
behaviour indicative of anxiety. These findings are consistent with past research of 
precipitated morphine withdrawal-induced anxiety (Schulteis et al., 1998; Zhang & 
Schulteis, 2008). No alterations of locomotor activity were observed in animals treated 
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with morphine, naloxone, or morphine and naloxone based on closed arm entries on the 
EPM and incidence of rearing during social interaction. Although morphine-induced 
hyperactivity was recorded in Experiment 2, this discrepancy is likely attributable to the 
short duration and single trials of the anxiety tests. Nonetheless, this finding agrees with 
previous similar studies (Schulteis et al., 1998; Zhang & Schulteis, 2008). 
General Discussion 
Results of the present study can be summarized as follows: (1) consistent with 
past research, administration of SR141716 produced physical signs of withdrawal in rats 
chronically exposed to THC; (2) as previously observed, SRI41716 induced withdrawal-
like behaviour in THC-nai've rats, but to a lesser extent than in dependent rats; (3) 
precipitated THC withdrawal failed to produce a conditioned cue avoidance; (4) 
increased anxiety was observed in rats withdrawing from THC, but this increase was not 
dissimilar to anxiety induced by THC on its own; (5) naloxone-precipitated morphine 
withdrawal produced a significant conditioned cue avoidance following three 
conditioning trials and induced clear anxiogenic-like behaviour, confirming the validity 
of the tests. 
Collectively, these results present novel evidence that SR141716-precipitated 
THC withdrawal induces a somatic manifestation of drug withdrawal in the absence of a 
clear dysphoric or anxiogenic state. This withdrawal pattern is peculiar as cessation of 
other drugs of abuse produces distinct and conjunct somatic and dysphoric signs. 
Interestingly, however, adaptive neurophysiological responses to THC withdrawal are 
similar to those produced by withdrawal from opiates. 
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An increase of adenylyl cyclase (AC) activity is observed in the cerebellum 
during SR141716-precipitated THC withdrawal, which could be due to a compensatory 
response to the persistent inhibition of AC during chronic THC treatment (Hutcheson et 
al., 1998). Similarly, naloxone-precipitated morphine withdrawal is expressed at the 
cellular level by the upregulation of AC activity in brain regions with high opioid 
receptor populations, such as the locus coeruleus, and upregulation of the cyclic 
adenosine monophosphate (cAMP) pathway has been directly related to behavioural 
expression of precipitated morphine withdrawal (Duman, Tallman, & Nestler, 1988; 
Matthes et al., 1996; Rasmussen, Beitner-Johnson, Krystal, Aghajanian, & Nestler, 
1990). Neuroadaptive changes in the AC system may also help to clarify the lack of 
dysphoric and anxiogenic effects of THC withdrawal. In fact, the absence of adaptive 
changes of the AC system in brain structures other than the cerebellum, such as the 
mesolimbic system or the autonomic areas, may explain the lack of dysphoric effects of 
SR141716-precipitated THC withdrawal (Hutcheson et al., 1998). Morphine withdrawal, 
on the other hand, induces changes in the striatum and periaqueductal gray (PAG; 
Matthes et al., 1996), which correlates with the aversive properties of naloxone-
precipitated morphine withdrawal. 
Elevations in CRF and c-fos expression in the amygdala and other stress-
responsive brain sites during precipitated cannabinoid withdrawal (Rodriguez de Fonseca 
et al., 1997) are also common to withdrawal from opiates (Beckmann, Matsumoto, & 
Wilce, 1995). Furthermore, these increases have been correlated with the progression of 
physical signs of cannabinoid withdrawal, primarily implicating the basal ganglia in the 
motor component of cannabinoid withdrawal (Rodriguez de Fonseca et al., 1997). 
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Interestingly, however, the study demonstrating anxiety-like responses on the EPM in 
mice undergoing SR141716-precipitated THC withdrawal reported barely detecting 
somatic signs of withdrawal (Huang et al., 2010). This suggests that the physical and 
affective effects of cannabinoid withdrawal may be mediated by different neural 
mechanisms, which could explain the results of the current study. 
If the physical and affective aspects of cannabinoid withdrawal are mediated by 
distinct neural mechanisms, it is possible that these mechanisms are progressively 
engaged as withdrawal unfolds. Thus, concurrently examining affective manifestations of 
withdrawal when physical signs are exhibited may actually serve to overlook dysphoria 
and anxiety. And, although anxiety is often included under the umbrella of a negative 
affective state, it is possible that even dysphoric and anxiogenic aspects of cannabinoid 
withdrawal are mediated by separate systems and temporally misaligned. This has 
recently been suggested for morphine withdrawal (Rothwell et al., 2009). Systematic 
examination of the time course of peak neural changes associated with physical and 
affective states of withdrawal may provide helpful direction. 
Aside from the possibility that somatic and affective signs of cannabinoid 
withdrawal are mediated by temporally exclusive mechanisms, the neurophysiological 
consequences of cannabinoid withdrawal are similar to those of drugs exerting a negative 
motivational drive during withdrawal. This has been suggested to account for the 
continued use of cannabis in humans (Rodriguez de Fonseca et al., 1997). Of course, as 
demonstrated in the current study, behavioural effects of withdrawal from cannabinoids 
and opioids are distinct in vivo. These discrepant findings could result simply from the 
magnitude of the withdrawal induced by discordant dosing regimens of THC and 
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morphine and their respective receptor antagonists. Indeed, THC and SR141716 
independently produce differential effects at small and large doses (Hutcheson et al., 
1998; Sanudo-Pena et al., 1997). Furthermore, downregulation of CB1 receptors 
associated with tolerance during repeated exposure to cannabinoids (Dill & Howlett, 
1987) may require increasing doses over time in order to observe an aversive state 
induced by SR141716-precipitated withdrawal. However, interrupting cannabinoid 
treatment with antagonist challenges—as in conditioning trials of the cue avoidance 
task—may interfere with the effects of chronic cannabinoid exposure, and perhaps reduce 
the severity of withdrawal. 
Finally, although SRI 41716 provides a valuable animal model of cannabis 
withdrawal, and there is general agreement that this antagonist produces a valid physical 
withdrawal syndrome (Aceto et al., 1995; Diana et al., 1998; Moranta, Esteban, & 
Garcia-Sevilla, 2009; Tsou et al., 1995), there are important considerations for its use in 
these types of studies and the generalizability of the results. As previously discussed, 
SR141716 appears to have intrinsic activity, which may modify the true manifestations of 
cannabinoid withdrawal and explain the disconnect between physical and affective 
withdrawal characteristics. Whether the action of SRI 41716 is by inverse agonistic 
effects on the CB1 receptor or by antagonistic effects on the endogenous cannabinoid 
system remains to be determined. Further research is required to elucidate the 
biochemical and behavioural functions of SR141716 and its role in precipitated 
cannabinoid withdrawal. It would be prudent to investigate spontaneous cannabinoid 
withdrawal, despite the methodological difficulties, to corroborate results from 
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precipitated withdrawal studies. After all, SR141716 produces withdrawal-like effects 
that otherwise do not occur in spontaneous withdrawal. 
In conclusion, the present study is the first to demonstrate a dissociation between 
the physical and affective signs of cannabinoid withdrawal in rats, contributing to the 
divergent literature on the existence and clinical significance of a cannabis withdrawal 
syndrome. The behavioural model of precipitated cannabinoid withdrawal was 
confirmed, though the motivational effects of THC withdrawal are lacking. Although 
there are some similarities between THC and morphine withdrawal, results generally 
indicate that the consequences of abstaining from both drugs of abuse are fundamentally 
different and that withdrawal from THC is less intense. Based on these results, continued 
use of cannabis cannot be explained by the simple desire to alleviate negative aspects of 
withdrawal. However, future research on the relationship between amount or duration of 
cannabis use and the associated severity of withdrawal as well as the potential for relapse 
is necessary to resolve the clinical importance of a cannabis withdrawal syndrome. These 
findings could reveal the need for pharmacological and behavioural treatments to abate 
cannabis withdrawal. 
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T-VEH = THC vehicle; S-VEH = SR141716 vehicle; SR = 3 mg/kg SR141716; THC = 5 
mg/kg THC; WD = withdrawal. 
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Table 2 
Procedural timeline for Experiment 2A: SRI 417T16-precipitated THC Withdrawal-
induced Cue-conditioning, One Cycle 
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SR141716; THC = 5 mg/kg THC; M-VEH = morphine vehicle; N-VEH = naloxone 
vehicle; NAL = 1 mg/kg naloxone; MOR = 5 mg/kg morphine; WD = withdrawal. 
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Procedural timeline for Experiment 2B: SRI 41716-precipitated THC Withdrawal-
induced Cue-conditioning, Three Cycle 
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naloxone; MOR = 5 mg/kg morphine; WD = withdrawal. 
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Figure 1. Data for physical symptoms of SR141716-precipitated THC withdrawal. A: 
mean (±SEM) time spent scratching. SRI 41716 significantly increased time spent 
scratching in all animals (p=.003), and THC rats spent significantly more time scratching 
than T-VEH rats (p=.039). B: mean (±SEM) number of wet-dog shakes. SR141716 
significantly increased the number of wet dog shakes (p=.001). C: mean (±SEM) number 
of facial rubs. SR141716 significantly increased the number of facial rubs (p=.032). 
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Figure 2. SR141716-precipitated THC withdrawal significantly increased scratching 
behaviour. Mean (±SEM) time spent scratching. *p<.05, significantly different from T-
VEH. 
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Figure 3. SR141716-precipitated THC withdrawal did not significantly alter conditioned 
cue preference after one cycle of cue-conditioning. Mean (±SEM) change in time spent 
on SR141716-paired side between pre-test and test phase of one cycle cue-conditioning. 
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Figure 4. Locomotor activity data for THC groups during conditioning phase of one cycle 
cue-conditioning. A: mean (±SEM) distance traveled. B: mean (±SEM) time in motion. 
*p<.05, significantly different from T-VEH. THC-treated animals spent significantly less 
time in motion than T-VEH-treated animals (p=.042). C: mean (±SEM) absolute turn 
angle. 
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Figure 5. Naloxone-precipitated morphine withdrawal did not significantly alter 
conditioned cue preference after one cycle of cue-conditioning. Mean (±SEM) change in 
time spent on naloxone-paired side between pre-test and test phase of one cycle cue-
conditioning. 
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Figure 6. Locomotor activity data for morphine groups during conditioning phase of one 
cycle cue-conditioning. A: mean (±SEM) distance traveled. *p<.005, significantly 
different from N-VEH. B: mean (±SEM) time in motion. *p<.001, significantly different 
from N-VEH. C, mean (±SEM) absolute turn angle. *p<.005, significantly different from 
N-VEH. MOR-treated animals had a significantly lower absolute turn angle than M-
VEH-treated animals (p=.026). 
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Figure 7. SR141716-precipitated THC withdrawal did not significantly alter conditioned 
cue preference after three cycles of cue-conditioning Mean (±SEM) change in time spent 
on SR141716-paired side between pre-test and test phase of three cycle cue-conditioning. 
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Figure 8. Locomotor activity data for THC groups during conditioning phase of three 
cycle cue-conditioning. A: mean (±SEM) total distance traveled. THC-treated animals 
traveled significantly less distance than T-VEH-treated animals (p=.002); treatment with 
SR141716 significantly reduced distance traveled (p=.001); and all animals traveled a 
significantly greater distance on day one than on day two (p=.027) and day three 
(p=.007). B: mean (±SEM) time in motion. THC-treated animals spent significantly less 
time in motion than T-VEH-treated animals; and all animals spent significantly more 
time in motion on day one than on day three (p=.03). C: mean (±SEM) absolute turn 
angle. THC-treated animals had a significantly lower absolute turn angle than T-VEH-
treated animals (p<.001); treatment with SR141716 significantly reduced absolute turn 
angle (p=.016); and absolute turn angle was significantly greater on day one than on day 
two (p=.049) and day three (p=.041). 
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Figure 9. Naloxone-precipitated morphine withdrawal produced a significant conditioned 
cue avoidance after three cycles of cue-conditioning. Mean (±SEM) change in time spent 
on naloxone-paired side between pre-test and test phase of three cycle cue-conditioning. 
*p<.005, significantly different from M-VEH+NAL. 
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Figure 10. Locomotor activity data for morphine groups during conditioning phase of 
three cycle cue-conditioning. A: mean (±SEM) total distance traveled. MOR-treated 
animals traveled significantly greater distance than M-VEH-treated animals (p=.017); 
treatment with NAL significantly reduced distance traveled in all animals (p<.001); all 
animals traveled a significantly greater distance on day one than on day two (p=.024); 
MOR-treated animals traveled a significantly greater distance than M-VEH-treated 
animals during N-VEH-conditioning sessions; and MOR-treated animals traveled a 
significantly greater distance than M-VEH-treated animals on day 3 (p=.001). B: mean 
(±SEM) time in motion. MOR-treated animals spent significantly more time in motion 
than M-VEH-treated animals; treatment with NAL significantly reduced time spent in 
motion in all animals; MOR-treated animals spent significantly more time in motion than 
M-VEH-treated animals during N-VEH-conditioning sessions (p<.001); and MOR-
treated animals spent significantly more time in motion than M-VEH-treated animals on 
day 3 (p=.001). C: mean (±SEM) absolute turn angle. MOR-treated animals had a 
significantly greater absolute turn angle than M-VEH-treated animals (p=.038); treatment 
with NAL significantly reduced absolute turn angle in all animals (p<.001); absolute turn 
angle was significantly larger on day one than day two (p=.042); MOR-treated animals 
had a significantly greater absolute turn angle than M-VEH-treated animals during N-
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VEH-conditioning sessions; and MOR-treated animals had a significantly greater 
absolute turn angle than M-VEH-treated animals on day 3 (p=.001). 
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Figure 11. SR141716-precipitated THC withdrawal produced some anxiety-related 
behaviour on the emergence test, but it was not dissimilar to the behaviour induced by 
THC on its own. A: mean (±SEM) percent time spent in open field. B: mean (±SEM) 
number of entries to open field. *p<.005, significantly different from T-VEH+S-VEH. C, 
mean (±SEM) latency to first exit hide box. 
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Figure 12. Naloxone-precipitated morphine withdrawal significantly increased anxiety-
related behaviour on the emergence test. A: mean (±SEM) percent time spent in open 
field. *p<.01, significantly different from VEH+VEH; **p<.05, significantly different 
from M-VEH+NAL; ***p<.05, significantly different from MOR+N-VEH. B: mean 
(±SEM) number of entries to open field. *p<.05, significantly different from M-
VEH+NAL. C: mean (±SEM) latency to first exit hide box. 
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Figure 13. SR141716-precipitated THC withdrawal did not affect anxiety-related 
behaviour on the EPM. A: mean (±SEM) percent time spent in open arms. B: mean 
(±SEM) percent number of entries to open arms. C: mean (±SEM) number of entries to 
closed arms. 
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Figure 14. Naloxone-precipitated morphine withdrawal significantly increased anxiety-
related behaviour on the EPM. A: mean (±SEM) percent time spent in open arms. B: 
mean (±SEM) percent number of entries to open arms. *p<.005, significantly different 
from M-VEH+N-VEH; **p<.05, significantly different from M-VEH+NAL. C: mean 
(±SEM) number of entries to closed arms. 
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Figure 15. SR141716-precipitated THC withdrawal produced some anxiety-related 
behaviour during social interaction with an unfamiliar conspecific, but it was generally 
similar to anxiety-related behaviour induced by THC on its own. A: mean (±SEM) time 
spent sniffing other rat. *p<.005, significantly different from T-VEH+S-VEH; **p<.05, 
significantly different from T-VEH+SR. B: mean (±SEM) time spent following other rat. 
*p<.05, significantly different from T-VEH+S-VEH; **p<.05, significantly different 
from T-VEH+SR. C: mean (±SEM) time spent grooming other rat. D: mean (±SEM) 
number of rears. **p<.001, significantly different from T-VEH+SR. 
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Figure 16. Naloxone-precipitated morphine withdrawal significantly increased anxiety-
related behaviour during social interaction with an unfamiliar conspecific. A: mean 
(±SEM) time spent sniffing other rat. *p<.01, significantly different from M-VEH+N-
VEH; **p<.05, significantly different from M-VEH+NAL. B: mean (±SEM) time spent 
following other rat. *p<.05, significantly different from M-VEH+N-VEH. C: mean 
(±SEM) time spent grooming other rat. *p<.01, significantly different from M-VEH+N-
VEH. D: mean (±SEM) number of rears. 
